quotes and stock data delayed 15 minutes
Burn Rate (Qtr)
CYTK is developing potential medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function, like heart failure, hypertrophic cardiomyopathies (HCM), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). By focusing on impacting the mechanics of muscle with investigational medicines that may improve strength, power, or performance, CYTK aspires to develop new treatment options that may dramatically improve the lives and functionality of people living with debilitating diseases.
Click on drug name or indication to see upcoming trial info, prior data, and more general information
Drug | Disease (links)
Stage (next event)
See what the community is saying - click to see full post